The tinnitus patch Antinitus’s first study has been published in a major medical journal about tinnitus
20 July, 2017 / Written by Antinitus
Antinitus’s first clinical study (Aktin I) has undergone a peer review, a comprehensive scientific review, and was published in the International Tinnitus Journal in June 2017. This gives the product Antinitus additional validity and scientific recognition.
The International Tinnitus Journal (ITJ) was founded in 1995 and is a well-known medical journal for critical analysis of and the publication of new findings in tinnitus and balance disorders. ITJ is indexed on Medline, Embase, Excerpta Medica and Chemical Abstracts.
The study (Aktin I) was, as commissioned by Antinitus AB, carried out by Karolinska Trial Alliance, a clinical research centre aimed at enabling and conducting clinical studies within the Stockholm County Council (Stockholms Läns Landsting). Karolinska Trial Alliance belongs to Karolinska University Hospital, one of Europe’s largest hospitals.
“We welcome the opportunity to communicate our data and respond to questions about the performance of Antinitus. We will continue our work regarding future clinical studies and PMCF (Post-Market Clinical Follow-up) with feedback from the product’s users to further verify and develop the product’s effects and performance”, says Tommy Rönngren, Chairman of the Board at Antinitus AB.
See the published study at www.tinnitusjournal.com, reference: Ahnblad P. Pilot Investigation of a Topographical Filter Dermal Patch in Patients with Tinnitus. Int Tinnitus J. 2017; 21(1): 6–12.
Antinitus® is a Swedish innovation in the form of a crescent-shaped patch that can relieve the discomfort of tinnitus. The skin-friendly patch is applied behind the ear and is very easy to use. The treatment period is three weeks and the patch is replaced every day for hygienic reasons. The patch releases no substances or medications and one can live a completely normal life during the course of treatment. Clinical studies in Sweden show that at least 50% experience relief of their tinnitus discomfort and without the risk of serious side effects.